Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of alpha 1-antitrypsin deficiency

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Bouchecareilh, M.
  • Hutt, D. M.
  • Szajner, P.
  • Flotte, T. R.
  • Balch, William E.

publication date

  • November 2012

journal

  • Journal of Biological Chemistry  Journal

abstract

  • α1-Antitrypsin (α1AT) deficiency (α1ATD) is a consequence of defective folding, trafficking, and secretion of α1AT in response to a defect in its interaction with the endoplasmic reticulum proteostasis machineries. The most common and severe form of α1ATD is caused by the Z-variant and is characterized by the accumulation of α1AT polymers in the endoplasmic reticulum of the liver leading to a severe reduction (>85%) of α1AT in the serum and its anti-protease activity in the lung. In this organ α1AT is critical for ensuring tissue integrity by inhibiting neutrophil elastase, a protease that degrades elastin. Given the limited therapeutic options in α1ATD, a more detailed understanding of the folding and trafficking biology governing α1AT biogenesis and its response to small molecule regulators is required. Herein we report the correction of Z-α1AT secretion in response to treatment with the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA), acting in part through HDAC7 silencing and involving a calnexin-sensitive mechanism. SAHA-mediated correction restores Z-α1AT secretion and serpin activity to a level 50% that observed for wild-type α1AT. These data suggest that HDAC activity can influence Z-α1AT protein traffic and that SAHA may represent a potential therapeutic approach for α1ATD and other protein misfolding diseases.

subject areas

  • Calnexin
  • Cell Line
  • Dose-Response Relationship, Drug
  • Endoplasmic Reticulum
  • Gene Expression
  • HCT116 Cells
  • Histone Deacetylase Inhibitors
  • Histone Deacetylases
  • Humans
  • Hydroxamic Acids
  • Immunoblotting
  • Liver
  • Membrane Glycoproteins
  • Mutation
  • Oxidoreductases
  • Protein Folding
  • Protein Transport
  • Proteostasis Deficiencies
  • RNA Interference
  • Reverse Transcriptase Polymerase Chain Reaction
  • alpha 1-Antitrypsin
  • alpha 1-Antitrypsin Deficiency
scroll to property group menus

Identity

PubMed Central ID

  • PMC3488095

International Standard Serial Number (ISSN)

  • 0021-9258

Digital Object Identifier (DOI)

  • 10.1074/jbc.M112.404707

PubMed ID

  • 22995909
scroll to property group menus

Additional Document Info

start page

  • 38265

end page

  • 78

volume

  • 287

issue

  • 45

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support